Argatroban "reversal" is caused by nonphysiologic stimulation of coagulation, not activated factor VII.
Tanaka
Kenichi A
KA
Szlam
Fania
F
Koyama
Kaoru
K
Levy
Jerrold H
JH
D000925:Anticoagulants / Q000037:antagonists & inhibitors*; D001120:Arginine / Q000031:analogs & derivatives; D001777:Blood Coagulation / Q000502:physiology*; D015942:Factor VIIa / Q000502:physiology*; D006801:Humans; D007616:Kaolin / Q000009:adverse effects; D010592:Pharmaceutic Aids; D010875:Pipecolic Acids / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D013449:Sulfonamides; D013916:Thrombelastography; D013917:Thrombin / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D010592:Pharmaceutic Aids; D010875:Pipecolic Acids; D013449:Sulfonamides; D007616:Kaolin; D001120:Arginine; D015942:Factor VIIa; D013917:Thrombin; C031942:argatroban